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OBJECTIVES The aim of this retrospective study was to evaluate perinatal atrial flutter (AF) and the efficacy
of maternally administered antiarrhythmic agents, postpartum management and outcome.
BACKGROUND Perinatal AF is a potentially lethal arrhythmia, and management of this disorder is difficult
and controversial.
METHODS Forty-five patients with documented AF were studied retrospectively.
RESULTS Atrial flutter was diagnosed prenatally in 44 fetuses and immediately postnatally in 1 neonate.
Fetal hydrops was seen in 20 patients; 17 received maternal therapy, 2 were delivered and 1
was not treated because it had a severe nontreatable cardiac malformation. In the nonhydropic
group of 24 patients, 18 were treated and the remaining 6 were delivered immediately. In the
hydropic group, 10 received single-drug therapy (digoxin or sotalol) and 7 received multidrug
therapy. In the nonhydropic group, 13 received a single drug (digoxin or sotalol) and 5
received multiple drugs. One patient with rapid 1:1 atrioventricular conduction (heart rate
480 beats/min) died in utero and another died due to a combination of severe hydrops because
of the AF, sotalol medication, stenosis of the venous duct and hypoplastic placenta. Of the
43 live-born infants, 12 were in AF at birth. Electrical cardioversion was successful in eight
of nine patients. No recurrences in AF have occurred beyond the neonatal period. Four
patients with fetal flutter and hydrops showed significant neurological pathology immediately
after birth.
CONCLUSIONS Fetal AF is a serious and threatening rhythm disorder; particularly when it causes hydrops, it may
be associated with fetal death or neurological damage. Treatment is required and primarily aimed
at reaching an adequate ventricular rate and preferably conversion to sinus rhythm. Digoxin failed
in prevention of recurrence at time of delivery in a quarter of our patients, whereas with sotalol no
recurrence of AF has been reported, suggesting that class III agents may be the future therapy.
Once fetuses with AF survive without neurological pathology, their future is good and prophylaxis
beyond the neonatal period is unnecessary. (J Am Coll Cardiol 2000;35:771–7) © 2000 by the
American College of Cardiology
Atrial flutter (AF) is an uncommon form of tachycardia in
infancy and childhood, the management and particularly the
pharmacological treatment of which continue to pose a
challenge to clinicians and electrophysiologists. This per-
tains even more to perinatal AF, a rhythm disorder in which
the rate differs from that seen in adult patients and of which
underlying etiology and pathophysiology (in the presence or
absence of structural heart disease and secondary atrial
dilation) still need to be determined in humans. The
description of intrauterine AF by Carr and McLure (1) in
1931 is probably the first published report; Blumenthal et al.
(2) documented intrauterine AF with the use of fetal
electrocardiography in 1968. Currently, fetal echocardiog-
raphy is the best method and remains the cornerstone for in
utero diagnosis.
Observations from the early reports (1–5) of AF in the
fetus and newborn infant include a rapid intrauterine heart
rate and an abrupt irregular rhythm. Postnatal electrocar-
diograms (ECGs) show typical AF waves type I, the
common form of AF. In 1965, Hassenruck et al. (6) were
the first to report successful direct current cardioversion
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(DCC) of a newborn with AF. The next successful outcome
was not published until 1972 by Barclay and Barr (7). The
purpose of our retrospective study was to present our
experience with 45 fetuses with AF, 44 diagnosed in utero.
The course, management and outcome are analyzed.
PATIENTS AND METHODS
Our multicenter, retrospective study comprised 45 patients,
44 fetuses with AF diagnosed in utero and one neonate with
long-standing AF (probably from 24 weeks’ gestation)
diagnosed only at birth. The review includes patients with
AF referred from obstetrical units because of an irregular or
fast fetal heart rate from January 1984 to December 1998.
Cross-sectional echocardiography, M-mode and echo-
Doppler were used for diagnosis. Conventional fetal echo-
cardiographic views of the heart were obtained to exclude
structural heart malformation. Atrial rate was determined
using M-mode echocardiography, while ventricular rate was
determined with the use of M-mode and/or echo-Doppler.
A complete fetal scan was simultaneously performed to
determine indices of fetal growth, the presence of hydrops,
hydramnion or associated anomalies.
The decision to institute maternofetal therapy was related
to gestational age at presentation, state of lung maturity and
the presence of hydrops. Mode of delivery was decided
based upon the fetal condition and the further stress that
vaginal delivery might impose.
RESULTS
Forty-four fetuses with in utero AF were diagnosed at a
median gestational age of 31.5 weeks, range 19 weeks to 40
weeks. At time of presentation, mean atrial rate was
450/min (median 440, SD 42.8) and mean ventricular rate
was 224/min (median 220, SD 21.8). At time of diagnosis,
20 out of 44 fetuses were hydropic.
Maternofetal therapy. As outlined in Figure 1, 17 out of
20 hydropic fetuses received therapy. Nine of these received
single-drug therapy with digoxin (loading dose of 1500 mg
and maintenance dose of 250 mg twice daily) and one with
Abbreviations and Acronyms
AF 5 atrial flutter
AV 5 atrioventricular
CTG 5 cardiotonography
DCC 5 direct current cardioversion
HLHS 5 hypoplastic left heart syndrome
TVAOP 5 transvenous atrial overdrive pacing
Figure 1. Allocation of fetal patients with atrial flutter into two study groups at time of recognition: hydropic and nonhydropic. Patients
are further subdivided into treated and nontreated for each group. Assoc. HLH 5 associated hypoplastic left heart syndrome;
Dig/Sot/Proc/Quin/Flec/Prop 5 digoxin/sotalol/procainamide/quinidine/flecainide/propaphenone. The bottom boxes describe the
number of cases with atrial flutter at birth per number of infants born alive.
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sotalol (80 mg q 8 h). In this group, one patient died in
utero shortly after diagnosis and 2 h after maternal loading
with intravenous (IV) digoxin. The AF was associated with
1:1 atrioventricular (AV) conduction, with a ventricular rate
of 480/min. This ventricular rate, and not the initiation of
digoxin therapy, probably caused the demise of this fetus.
Another patient was treated with sotalol and died abruptly
intrauterine at 38 weeks’ gestation within 24 h after the oral
sotalol medication was increased to 160 mg q 12 h, because
of persisting AF. This could very well be a pro-arrhythmic
effect, but in this hydropic patient an associated hypoplastic
ductus venosus was found at autopsy. Of the remaining
eight patients, one was in AF at time of birth.
Seven of the 20 hydropic fetuses received more than one
drug, digoxin, as the drug of first choice in each. Drug
combinations included digoxin and procainamide, quini-
dine, flecainide, propaphenone and sotalol. One of these
patients received direct umbilical vein digoxin and procain-
amide. Of these seven patients, three (including the latter)
were born in AF. Of the 24 nonhydropic patients, 18 were
treated. Thirteen of them had single therapy, five with
digoxin and eight with sotalol. The remaining five patients
received a combination of digoxin and sotalol. Table 1
contains a summary of clinical data, and dosages for the
different drugs are indicated in Table 2.
Surveillance of mother and fetus occurred twice weekly.
Fetal heart rate was examined, and the mother was ques-
tioned on subjective maternal complaints; but no maternal
problems other than slight dizziness occurred. All mothers
had an ECG made before therapy initiation, but no irreg-
ular heart rates were found. No blood levels were measured
during the period of this review, but recently this policy has
been changed, and blood levels are monitored. Before a
second drug was introduced, the initial therapy was maxi-
mized (sotalol 3*160 mg and digoxin 3*0.125 mg).
Nontreated fetuses. Three of the 20 hydropic patients
were not treated, one due to an associated hypoplastic left
heart syndrome (HLHS) and the other two were delivered
soon after diagnosis because they were near term. Six of the
24 nonhydropic fetuses received no medication, as they were
delivered within a week of diagnosis and beyond 35 weeks of
gestation (when the lungs were assumed to be mature).
Structural heart disease. Only one of the 44 fetuses was
found to have a cardiac malformation. Atrial flutter in this
fetus was detected at 19 weeks’ gestation, and a HLHS was
diagnosed. In light of the prognosis a decision was made not
to treat, and spontaneous delivery occurred at 29 weeks’
gestation.
Mode of delivery. Delivery through means of a cesarean
section was deemed necessary in 10 of the 44 fetuses
(median gestational age 37 weeks, range 30 to 40 weeks) as
normal vaginal delivery was considered to impose further
stress on an already compromised heart. Cesarean section
was performed soon after presentation and diagnosis of AF
in five cases, which were not treated. A hydropic fetus
diagnosed at 33 weeks was treated with digoxin for 24 h
with no improvement and was therefore delivered by cesar-
ean section. In another fetus presenting at 34 weeks,
maternofetal digoxin was administered for four weeks be-
fore cesarean section delivery. In a third patient presented at
35 weeks, sotalol and digoxin failed to establish normal
sinus rhythm, and delivery was performed at 39 weeks by
cesarean section.
Atrial flutter at birth. Of the original 45 patients, 2
patients died in utero, and 12 of the 43 live-born infants
were in AF at birth. Twelve-lead ECG confirmed AF with
monomorphic undulating negative flutter waves in leads II,
III, and avF (common type). Flutter waves were commonly
seen in lead V1. No sign of aberrant conduction was noted
on these ECGs. Three infants were in serious trouble with
poor Apgar scores at birth.
Nine of the 12 patients in AF received DCC as initial
treatment. Eight of these converted to sinus rhythm. One
patient remained in AF despite undergoing subsequent
transvenous atrial overdrive pacing (TVAOP). This baby
received a multitude of medications including IV digoxin
and procainamide. Loading with IV amiodarone and repeat
TVAOP were successful in conversion to sinus rhythm.
One other patient born with AF initially underwent
unsuccessful TVAOP and reverted to sinus rhythm after
electrocardioversion.
Two patients were treated medically, one with digoxin
alone, the other with digoxin and quinidine. Both reverted
to sinus rhythm on medication.
In one other patient, AF had not been diagnosed before
birth. At 26 weeks’ gestation polyhydramnion had been
detected, and an irregular CTG (cardiotonography) sug-
gested a possible existence of AF, but this was not recog-
nized and no further investigations or treatment were
performed. Delivery at 39 weeks revealed a hydropic and
acidotic baby with extremely poor Apgar score requiring
immediate resuscitation and artificial ventilation. On refer-
ral, the pulse was irregular, between 120 and 140 beats/min.
Blood pressure was low, 40/22, mean 29 mm Hg. A narrow
QRS rhythm could be seen on ECG, but no detectable
P waves. Twelve-lead ECG confirmed AF at a rate of 480
to 540 beats/min with varying AV block. On cross-sectional
echocardiography the atria were markedly dilated and seen
to flutter, while the ventricles were dilated. Synchronized
electrocardioversion was successful. The infant was digi-
talized. Over the ensuing 4 h the rhythm changed from AF
with varying block to AV reentry supraventricular tachycar-
dia with ventricular rates of up to 300/min. Six hours later
the infant was in sinus rhythm with a good blood pressure
and improved peripheral perfusion. Ultrasound of the head
showed evidence of cortical necrosis most likely on the basis
of long-standing cerebral hypoperfusion. Two days later the
child died from cerebral inactivity. Figure 2 indicates
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outcome and treatment strategy after birth for the whole
study group.
Neurological complications. In four of the 45 patients,
including the one described above, neurological morbidity
was documented immediately postnatally, suggesting an
association with the prenatally existing arrhythmia. The
neurological damage ranged from severe cerebral hypoxic-
ischemic lesions to intraventricular hemorrhage, resulting in
a hydrocephalus. One patient had a small periventricular
infarction that is resolving.
Management and follow-up. Prophylactic antiarrhythmic
medication was given to 25 of the infants. Median duration
Table 1. Summary of Clinical Data
Pt
GA at
Recognition
(Weeks) Hydrops
In Utero
Treatment
Delivery
Mode
GA
(Weeks) AF at Birth
Treatment
at Birth
Duration of
Prophylaxis
(Months)
1 40 2 no cs 40 yes DCC 12
2 36 2 yes nvd 40 no no 1.25
3 33 1 yes cs 33 yes DCC 7.5
4 37 2 no cs 37 yes DCC 6
5 34.3 2 yes cs 35 yes DCC 7
6 39 2 no nvd 40 no no no
7 34 2 yes nvd 36 no no 9
8 37 2 no nvd 38 no no no
9 35 2 no cs 35 yes TVAOP 12
10 19 1 yes nvd 38 no no 12
11 29 1 yes cs 30 yes yes 6
12 35 1 no cs 35 yes DCC 3
13 24 1 yes nvd 39 yes yes 6
14 19 1 no nvd 29 no HLHS no
15 28 1 yes nvd 38 yes yes 12
16 36 2 yes nvd 40 no no no
17 37 2 no nvd 37 yes DCC 9
18 37 2 yes nvd 41.5 yes DCC 12
19 34 2 yes cs 38 no no 12
20 34 2 yes nvd 38 no no 12
21 — 1 no nvd 39 yes DCC died day 2
22 32 1 yes nvd 37 no no 3
23 33 1 yes nvd 38 no no 12
24 36 1 yes nvd 38 no no 6
25 36 2 yes nvd 38 no no no
26 34 1 yes nvd 37 no no 3
27 34 1 yes nvd 37 no no 6
28 35 1 yes nvd 39 no no 3
29 28 1 yes nvd 36 no no no
30 31 1 yes nvd 38 died in utero died in utero died in utero
31 36 1 yes nvd 38 no no no
32 38 1 yes nvd 39 no no no
33 — 1 yes nvd 36 no yes yes
34 31 1 no cs 35 no no no
35 2 yes nvd 34 no no no
36 35 2 yes cs 39 no no no
37 36 2 yes nvd — no no no
38 30.2 2 yes nvd — no no no
39 20.5 2 yes nvd 40.2 no no no
40 31 2 yes nvd 39 no no no
41 34 2 yes nvd 34.3 no no no
42 — 2 yes nvd 36 no yes 0.75
43 30 2 yes nvd 2 no no no
44 36 2 yes nvd 39 no yes yes
45 33.3 1 yes nvd 39 died in utero died in utero died in utero
GA 5 gestational age; cs 5 cesarean section; nvd 5 normal vaginal delivery; DCC 5 direct current cardioversion; AF 5 atrial flutter; TVAOP 5 transvenous atrial overdrive
pacing; HLHS 5 hypoplastic left heart syndrome pacing.
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of prophylaxis was 7.25 months and ranged from three
weeks to 12 months. Prophylactic antiarrhythmic drugs
included digoxin alone in 17 patients, digoxin and quinidine
in one patient, digoxin and sotalol in one patient and sotalol
alone in six patients.
Recurrence of AF after initial conversion to sinus rhythm
did not occur in any of the patients. Long-term follow-up
for the group ranges between six months to 10 years and
three months, median five years and two months.
DISCUSSION
Early reports. Atrial flutter is a primary atrial tachyar-
rhythmia confined solely to the atrium. The specialized AV
conduction system does not participate in the primary
mechanism. Early reports (1–5,8) of AF in the fetus and
newborn stressed that the intrauterine heart rate was rapid,
the rhythm was abruptly irregular. Digoxin did not seem to
be effective in converting the rhythm to sinus and after birth
Figure 2. Outcome for the entire study group and treatment strategy for neonates in atrial flutter after birth. DCC 5 direct current
cardioversion; TVAOP 5 transvenous atrial overdrive pacing; Death 5 death due to a neurological cause.
Table 2. Drugs Used for Control of Fetal AF
Drug Dose
Maternal
Therapeutic Concentration
Fetal:Maternal
Concentration Ratio
Digoxin Loading:
IV 3 dd 1.5 mg
Maintenance:
po 0.25 to 1.0 mg/day
1–2 mg/ml 0.6:1
Flecainide Loading:
po 2 dd 150 mg
Maintenance:
po 2 dd 100 mg
0.2–1 mg/ml 0.86:1
Sotalol Maintenance:
po 160–320 mg/24 h
2–7 mg/ml 1.05:1
Amiodarone Loading:
po 1200 mg/24 h
Maintenance:
po 400–600 mg/24 h
Amiodarone: 1–2.5 mg/ml
Desethylaminodarone 0.2–2.6 mg/ml
0.1–0.3:1
IV 5 intravenous; po 5 per os.
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the ECG showed typical flutter waves. Furthermore, if the
infant had a cardiac malformation, the prognosis was poor.
Even in the absence of associated structural heart disease the
prognosis has been reported to be poor.
Our series. In our series of 45 patients with perinatal AF,
the mortality and neurological morbidity were each 9% and
were confined to the subgroup of hydropic fetuses. One
patient died postnatally from severe associated structural
heart disease (hypoplastic left heart syndrome) and another
intrauterine after treatment with digoxin. We do not con-
sider this patient’s death a consequence of digoxin therapy,
because under ideal circumstances, transplacental passage of
this drug is slow (up to a few days) in order to achieve an
adequate therapeutic level in the fetus. In this patient with
a hydropic placenta, the transplacental transfer of digoxin
was further hampered. At autopsy an accessory AV connec-
tion was identified, which we contend was responsible for
the 1:1 AV conduction.
In the third severely hydropic patient, AF had been
missed before birth, but was present immediately after birth.
Despite successful DCC after birth, the patient ultimately
died from cerebral damage probably due to long-standing
and/or fluctuating cerebral hypoperfusion as a result of
intrauterine AF.
Three patients were delivered by cesarean section, al-
though no cases of hydrops were present, because patients
were near term and at that time therapy was considered to
be more effective out of utero. Since then the policy has
been changed in favor of vaginal delivery as no positive effect
of cesarean section has been discovered.
Potential mortality and morbidity. The potentially lethal
outcome in perinatal AF is not to be underestimated.
Moller et al. (3) were the first to report increased birth
weight, which suggested to them the presence of anasarca
from intrauterine cardiac failure secondary to arrhythmia. In
1970 van der Horst (9) reported a case of fetal hydrops
secondary to intrauterine AF. In 1969, Moller et al. (5)
reviewed the outcomes in 36 infants with AF. Nine infants
died, of whom six had received digoxin but failed to
respond.
Even more worrisome were the four patients in the
present study with neurological damage. In a previous
publication we reported the assumption that AF was re-
sponsible for the disturbance of the maintenance of ade-
quate cerebral perfusion (10). This causes loss of cerebro-
vascular autoregulation and will result in a pressure-passive
phenomenon, whereby a reduction or increase in mean
arterial blood pressure is accompanied by a concomitant
reduction or increase in cerebral blood flow. In the dis-
tressed newborn, cerebral autoregulation is lost, exposing
the brain to ischemia in even moderate hypotension and to
an increased pressure gradient across the capillary wall in
even moderate hypertension, with increased risk of intra-
cranial hemorrhage (11). Experimental studies in the fetal
lamb have shown that this certainly applies to the distressed
fetus in utero; a period of intrauterine distress causes
abolition of cerebral autoregulation leading to severe im-
pairment of the maintenance of constant cerebral perfusion
(12,13). A fetus presenting with hemodynamic compromise
and hydrops secondary to fetal tacharrhythmia is therefore
at increased risk of development of a pressure-passive
cerebral circulation and the cerebral complications that may
result from this.
Intrauterine treatment. In light of these findings, we have
opted for a policy to treat all fetuses with AF at time of
presentation, unless immediate delivery is possible. Despite
active treatment in most cases, we were confronted with AF
at birth in 18% of patients (six out of 34 live-born patients).
Conversion to sinus rhythm in our patients while receiving
maternofetal therapy is a debatable issue. Was this indeed a
result of the antiarrhythmic medication or was it part and
parcel of the natural history of AF in these patients? One
may postulate that both a paroxysmal and sustained form of
AF exists in the fetus and newborn infant, as is seen with
adult patients. Alternatively, we are unsure whether the
stress of delivery and release of catecholamines may have an
influence on retriggering the onset of AF, such as seen in
fetuses with supraventricular tachycardia (14).
Digoxin may be useful through its action in slowing
ventricular rate, allowing more ventricular filling, and im-
proving cardiac output. Its inability in breaking or convert-
ing AF to sinus rhythm in pediatric and adult patients has
been well documented (14–16). In the collaborative study
reported by Garson et al. (17), digoxin used alone was
successful in preventing recurrences of AF in only 44% of
patients. Wellens (18) stresses that digoxin is contraindi-
cated in the presence of an accessory pathway, which
conducts anterogradely. This is most likely to have been the
case in our fetus with 1:1 AV conduction.
These studies suggest that although digoxin has been
used for treatment in the past, it might have lost some of its
attraction for the treatment of AF. Alternatively, antiar-
rhythmic drug treatment with class I drugs is often unsuc-
cessful in the conversion of AF to sinus rhythm, possibly
explained by experimental data, suggesting that prolonga-
tion of the atrial-effective refractory period is more critical
than slowing conduction in the termination of reentrant
atrial flutter (19). Action potential prolongation in the
absence of conduction slowing seems more effective in
terminating human AF than depression of the excitability
(19).
Current literature in adult patients advocates the use of
class III agents such as sotalol. Sotalol appears to be an
effective agent in the treatment of AF, seems suitable in
treating the fetus, and has excellent transplacental passage in
a dosage regimen of 160 mg twice daily (20,21). Monitoring
of the maternal QT interval is essential in excluding
maternal pro-arrhythmia; fetal pro-arrhythmia, however, is
a troublesome aspect of this therapy and might force the
fetal cardiologist eventually to abandon this agent. Amio-
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darone, also a class III agent, has been used for fetal
arrhythmias but has many side effects and does not cross the
placenta as readily as does sotalol (22).
Dophitilide, a new class III agent, may be even more
promising in the future for both in utero treatments and in the
newborn infant (19). Although current data on the use of
dophitilide in the fetus and neonate are lacking, dophitilide is
found to be more effective than flecainide in the conversion of
AF to sinus rhythm in adult patients, yet flecainide produces a
more prolonged flutter cycle length (19).
Although both digoxin and sotalol are effective drugs in
the treatment of fetal AF, we use sotalol as the drug of
choice because digoxin transplacental passage is slower,
relapse into AF occurs more often at birth, and subjective
maternal complaints are more prominent than with sotalol.
Postnatal flutter and treatment. The relapse of patients at
birth into AF remains a troublesome issue and requires
intensive-care admission of these fragile patients. Synchro-
nized DCC (eight out of nine patients) was useful in the
conversion of AF to sinus rhythm (6,7), and TVAOP was
successful in one of two patients, and only after loading with
amiodarone. Esophageal or TVAOP has been used in
children to terminate atrial flutter (23,24).
Once AF is converted to sinus rhythm, one may elect to
wait and observe if flutter recurs (25). Alternatively, one
may elect to treat for six months to a year, although it
appears from this review that recurrence of AF is exceed-
ingly rare beyond the neonatal period. This questions the
need for prophylaxis; our current policy is not to treat
prophylactically.
Conclusions. Finally, we can state that AF is a serious and
life-threatening rhythm disorder of the human fetus. Spe-
cifically, when it causes hydrops it is associated with fetal
death or neurological damage. Treatment therefore is re-
quired, primarily aiming at reaching an adequate ventricular
rate and preferably conversion to sinus rhythm. It seems
important that relapses back and forth and in and out of
flutter should be prevented at all cost to protect the fetal
brain. Once fetuses with AF survive, their future is bright,
and prophylaxis beyond the neonatal period is unnecessary.
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